Exhibit 10.3
================================================================================
AMENDED AND RESTATED LICENSE, DEVELOPMENT AND
COMMERCIALIZATION AGREEMENT
BY AND BETWEEN
XXXXXXX-XXXXX SQUIBB COMPANY
(A DELAWARE CORPORATION)
AND
VANDA PHARMACEUTICALS, INC.
(A DELAWARE CORPORATION)
================================================================================
----------
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.
TABLE OF CONTENTS
PAGE
----
ARTICLE 1 DEFINITIONS................................................. 1
ARTICLE 2 LICENSE GRANT............................................... 8
2.1 Exclusive License Grant....................................... 8
2.2 Non Exclusive License Grant................................... 8
2.3 Sublicense.................................................... 8
2.4 No Trademark License.......................................... 8
2.5 No Implied Licenses........................................... 8
2.6 Marketing Arrangements........................................ 9
2.7 Retained Rights............................................... 9
ARTICLE 3 OPTION GRANTS............................................... 9
3.1 Vanda's Option: Third Party Development Partners.............. 9
3.2 BMS Option Exercisable Upon Completion of Phase III Clinical
Studies: Commercialization.................................... 10
3.3 Right of First Negotiation to Act as a Co-Promotion Partner
in Commercialization of a Product By Either Party............. 11
3.4 Responsibilities Regulatory Affairs........................... 12
ARTICLE 4 TRANSFER OF BMS KNOW-HOW;................................... 13
4.1 Transfer of BMS Compound Know-How............................. 13
4.2 Non-Solicitation.............................................. 14
ARTICLE 5 DEVELOPMENT................................................. 14
5.1 Program Liaison............................................... 14
5.2 Development................................................... 14
5.3 Development Reports........................................... 15
5.4 Records....................................................... 15
5.5 Development Responsibilities and Costs........................ 15
5.6 Regulatory Responsibilities and Costs......................... 15
ARTICLE 6 COMMERCIALIZATION........................................... 18
6.1 Commercializing Party's Responsibilities...................... 18
ARTICLE 7 MANUFACTURE AND SUPPLY...................................... 19
i
TABLE OF CONTENTS
(continued)
PAGE
----
7.1 Responsibility................................................ 19
7.2 Provision of Compound......................................... 19
7.3 Right to Manufacture Commercial Supply........................ 19
ARTICLE 8 PAYMENTS.................................................... 20
8.1 Technology Access Fee......................................... 20
8.2 Milestone Payments............................................ 20
8.3 Timing........................................................ 21
8.4 Development Costs............................................. 21
8.5 Royalty Payment............................................... 21
8.6 Third Party Royalty Payments.................................. 22
8.7 [*] Third Party Royalty Payments.............................. 22
8.8 Term for Royalty Payments..................................... 22
8.9 Sales Reports................................................. 23
8.10 Currency Exchange............................................. 24
8.11 Tax Withholding............................................... 24
8.12 Interest Due.................................................. 24
ARTICLE 9 REPRESENTATIONS AND WARRANTIES; DISCLAIMER; LIMITATION OF
LIABILITY................................................... 24
9.1 Mutual Warranties............................................. 24
9.2 BMS Warranties and Covenants.................................. 25
9.3 Vanda Warranties and Covenants................................ 25
9.4 DISCLAIMER.................................................... 25
9.5 Limitation of Liability....................................... 26
ARTICLE 10 PATENT MAINTENANCE; INFRINGEMENT; CONFIDENTIALITY........... 26
10.1 Inventions.................................................... 26
10.2 Patent Maintenance; Abandonment............................... 26
10.3 Enforcement of BMS Patent Rights Against Infrigers............ 27
10.4 Defense of Third Party Claims................................. 28
ARTICLE 11 NONDISCLOSURE OF CONFIDENTIAL INFORMATION................... 29
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
ii
TABLE OF CONTENTS
(continued)
PAGE
----
11.1 Nondisclosure................................................. 29
11.2 Authorized Disclosure......................................... 29
11.3 Terms of this Agreement....................................... 30
11.4 Exception for Disclosure [*].................................. 30
ARTICLE 12 INDEMNITY................................................... 31
12.1 Vanda Indemnity............................................... 31
12.2 BMS Indemnity................................................. 31
12.3 Indemnification Procedures.................................... 32
12.4 Insurance..................................................... 32
ARTICLE 13 TERM AND TERMINATION........................................ 33
13.1 Term.......................................................... 33
13.2 Termination By BMS............................................ 33
13.3 Termination by Vanda.......................................... 34
13.4 Effect of Termination......................................... 34
13.5 Survival...................................................... 37
13.6 Bankruptcy.................................................... 37
ARTICLE 14 MISCELLANEOUS............................................... 38
14.1 Provisions Contrary to Law.................................... 38
14.2 Third Party Rights............................................ 38
14.3 Notices....................................................... 39
14.4 Force Majeure................................................. 39
14.5 Use of Names.................................................. 39
14.6 Assignment.................................................... 40
14.7 Further Assurances............................................ 40
14.8 Waivers and Modifications..................................... 40
14.9 Choice of Law and Jurisdiction................................ 41
14.10 Publicity..................................................... 41
14.11 Entire Agreement.............................................. 42
14.12 Counterparts.................................................. 42
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
iii
TABLE OF CONTENTS
(continued)
PAGE
----
14.13 Relationship of the Parties................................... 42
14.14 Headings...................................................... 42
14.14 Dispute Resolution............................................ 42
iv
AMENDED AND RESTATED LICENSE, DEVELOPMENT AND
COMMERCIALIZATION AGREEMENT
THIS AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION
AGREEMENT (this "Agreement"), effective as of the Effective Date (defined
below), is made and entered into by and between XXXXXXX-XXXXX SQUIBB COMPANY, a
Delaware corporation headquartered at 000 Xxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx 00000
XXX ("BMS") and VANDA PHARMACEUTICALS, INC., a Delaware corporation having its
principal place of business at 00 Xxxxxxx Xxxxxx, Xxxxx 000, Xxxxxxxxx, XX 00000
("Vanda"). Each of BMS and Vanda is referred to herein as a "Party" and BMS and
Vanda are collectively referred to herein as the "Parties."
ARTICLE 1
DEFINITIONS
For the purposes of this Agreement, the following definitions shall apply, and
the terms defined herein in plural shall include the singular and vice-versa:
1.1 "AFFILIATE" means any corporation, company, partnership, joint venture
and/or firm which controls, is controlled by, or is under common control with a
specified person or entity. For purposes of this Section 1.1, "control" means
the power, direct or indirect, to direct the management and policies of an
entity, and shall be presumed to exist if one of the following conditions is
met: (a) in the case of corporate entities, direct or indirect ownership of at
least fifty percent (50%) of the stock or shares having the right to vote for
the election of directors, and (b) in the case of non-corporate entities, direct
or indirect ownership of at least fifty percent (50%) of the equity interest
with the power to direct the management and policies of such non-corporate
entities. The Parties acknowledge that in the case of certain entities organized
under the laws of certain countries outside of the United States, the maximum
percentage ownership permitted by law for a foreign investor may be less than
fifty percent (50%), and that in such cases such lower percentage shall be
substituted in the preceding sentence, provided that such foreign investor has
the power to direct the management and policies of such entity. Care Capital LLC
shall not be considered an Affiliate of Vanda and shall be considered a Third
Party if and only if Care Capital LLC (a) is not involved in the Development,
manufacture or Commercialization of a Product and (b) does not Control any
know-how or patent relating to any composition, formulation, method of use or
manufacture of a Compound or a Product that is not Controlled by Vanda and
Vanda's Affiliates (i.e., Care Capital does not Control any know-how or patent
that would be subject to Section 13.4.1(g) if Care Capital LLC was considered
an Affiliate of Vanda).
1.2 "APPROVAL" means Marketing Authorizations with pricing, labeling, and
reimbursement approvals and any other similar final approvals from the FDA or an
-1-
equivalent Regulatory Authority of another country necessary to manufacture
and/or Commercialize a Product.
1.3 "BMS COMPOUND PATENT RIGHTS" means (a) all U.S. patents and patent
applications and their foreign counterparts Controlled by BMS as of the
Effective Date covering the composition or utility of a Compound; (b) any
continuation, continuation-in-part (but only to the extent that such application
includes new data in support of claims previously submitted in a prior
originally filed application), divisional, and continued- prosecution
applications of any such patent applications in (a), and (c) any patents granted
on or issuing from any aforesaid applications in (a) and (b), including any
renewals, extensions, patents of addition, revivals, re-examinations, and
reissues thereof. Such Patent Rights are listed on Schedule 1.3.
1.4 "BMS COMPOUND KNOW-HOW" means all technical information and know-how
known to and Controlled by BMS, Effective Date (including, without limitation,
all biological, chemical, pharmacological, toxicological, clinical, assay, and
related know-how and trade secrets) identified by BMS as directly relating to,
and are reasonably useful for, the Development and/or Commercialization of a
Compound or Product in the manner that the Compound or Product has been
Developed and Commercialized by BMS heretofore.
1.5 "BMS KNOW-HOW" means the BMS Compound Know-How and the BMS
Manufacturing Know-How.
1.6 "BMS MANUFACTURING KNOW-HOW" means all technical information and
know-how known to and Controlled by BMS as of the Effective Date (including,
without limitation, all manufacturing data, the percentages and specifications
of ingredients, the manufacturing processes, specifications, technology, assays,
quality control and testing procedures, and related know-how and trade secrets)
identified by BMS as directly relating to, and are reasonably useful for, the
manufacture of a Compound or Product in the manner that the Compound or Product
has been manufactured by BMS heretofore.
1.7 "BMS MANUFACTURING PATENT RIGHTS" means those U.S. or foreign patents,
if any, Controlled by BMS as of the Effective Date, including any renewals,
extensions, patents of addition, revivals, re-examinations, and reissues
thereof, for which any claim covers the manufacture of a Compound in the same
manner that such Compound has heretofore been manufactured by BMS. Such patent
rights are listed on Schedule 1.7.
1.8 "BMS PATENT RIGHTS" means the BMS Compound Patent Rights and the BMS
Manufacturing Patent Rights.
1.9 "BUSINESS DAY" means a day other than Saturday, Sunday or any day on
which commercial banks located in New York are authorized or obligated by law to
close.
1.10 "COMBINATION PRODUCT" means a Product including [*]. For clarity, drug
delivery vehicles, adjuvants,
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-2-
and excipients shall not be deemed to be "active ingredients" the presence of
which in a Product would be deemed to create a Combination Product.
1.11 "COMMERCIALIZING PARTY" has the meaning set forth in Section 6.1.1.
1.12 "COMPOUNDS" means the compounds identified as BMS-214778 and
BMS-330446 each as specifically described in Schedule 1.3 and including without
limitation metabolites or prodrugs thereof, and any hydrates, conjugates, salts,
esters, isomers, polymorphs or analogues of any of the foregoing.
1.13 "COMMERCIALLY REASONABLE EFFORTS" means, with respect to a Product,
the carrying out of obligations [*], based on conditions then prevailing.
Commercially Reasonable Efforts requires that each Party: (a) [*] (b) [*] (c)
[*] and (d) [*].
1.14 "COMMERCIALIZATION" or "COMMERCIALIZE" means activities directed to
obtaining pricing and reimbursement approvals, marketing, promoting,
distributing, importing or selling a product
1.15 "CONFIDENTIAL INFORMATION" means all trade secrets, processes,
formulae, data, know-how, improvements, inventions, chemical or biological
materials, techniques, marketing plans, strategies, customer lists, or other
information that has been created, discovered, or developed by a Party, or has
otherwise become known to a Party, or which proper rights have been assigned to
a Party, as well as any other information and materials that are deemed
confidential or proprietary to or by a Party (including, without limitation, all
information and materials of a Party's customers and any other third party and
their consultants), regardless of whether any of the foregoing are marked
"confidential" or "proprietary" or communicated to the other by the disclosing
Party in oral, written, graphic, or electronic form. In the case of BMS,
"Confidential Information" shall include, without limitation, the BMS Know-How.
1.16 "CONTROLLED" OR "CONTROLS", when used in reference to intellectual
property, shall mean the legal authority or right of a Party hereto (or any of
its Affiliates) to grant a license or sublicense of intellectual property rights
to another Party, or to otherwise disclose proprietary or trade secret
information to such other Party, without breaching the terms of any agreement
with a Third Party, infringing upon the intellectual property rights of a Third
Party, or misappropriating the proprietary or trade secret information of a
Third Party.
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-3-
1.17 "DEVELOPMENT" means non-clinical and clinical drug development
activities reasonably related to the development and submission of information
to a Regulatory Authority, including without limitation toxicology, pharmacology
and other discovery efforts, test method development and stability testing,
process development, formulation development, delivery system development,
quality assurance and quality control development, statistical analysis,
clinical studies (including pre- and post- approval studies and specifically
excluding regulatory activities directed to obtaining pricing and reimbursement
approvals). When used as a verb, "Develop" means to engage in Development.
1.18 "DEVELOPMENT COSTS" means costs incurred by each Party that were
reasonably necessary for, and that reasonably relate to, the Development of a
Product in accordance with this Agreement and the Development Plan for that
Product, including, without limitation, (a) all [*] costs [*] incurred, (b) the
costs of "[*]" (c) [*] (d) [*] and (e) [*] costs [*].
1.19 "DEVELOPMENT PLAN" means the drug development plan for a Product
mutually agreed to in writing by the Parties, and as it may be amended by mutual
written agreement from time to time. It shall include, among other things,
budgets for Development of the Product that are planned to be conducted to
achieve each step towards preparation of an NDA for use of the Product in the
Field. The preliminary Development Plan for a Product containing the Compound
identified as BMS-214778 is attached hereto as Schedule 1,19.
1.20 "DOLLAR" means the lawful currency of the United States of America.
1.21 "EFFECTIVE DATE" means February 25, 2004.
1.22 "FDA" means the U.S. Food and Drug Administration or its successor
agency.
1.23 "FIELD" means the application to any human disease, disorder or
condition, including without limitation sleep disorders such as insomnia and
disorders of circadian rhythm.
1.24 "FIRST COMMERCIAL SALE" means, with respect to any Product, the first
sale for use or consumption by the general public of such Product in any country
in the
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-0-
Xxxxxxxxx after Marketing Authorization has been granted, or otherwise
permitted, by the governing health authority of such country.
1.25 "FTE RATE" means [*].
1.26 "IND" means an Investigational New Drug Application, as defined in the
United States Federal Food, Drug and Cosmetic Act filed with the FDA or its
foreign counterparts.
1.27 "INDEMNIFICATION CLAIM" has the meaning set forth in Section 12.1.
1.28 "JOINT INVENTIONS" has the meaning set forth in Section 10.1.
1.29 "LOSSES AND CLAIMS" has the meaning set forth in Section 12.1.
1.30 "MAJOR MARKET COUNTRY" means [*].
1.31 MANUFACTURING COST" means (i) [*] plus (ii) [*]. Annual adjustments to
variable overhead charges will be based on actual costs, while fixed overhead
will be adjusted annually based on changes from the previous year to the
Producer Price Index- Commodities Index for Drugs and Pharmaceuticals, as
published by U.S. Department of Labor, Bureau of Statistics (or successor
governmental authority). As an example of idle capacity charges, if a Party
reserves a capacity of [*] and actual demand is [*], then the idle plant for the
balance of [*] capsules will be included in the Manufacturing Cost; however, if
a Party needs [*] capsule capacity and BMS were to build a new plant for [*]
capsule capacity, then [*] capsule idle plant will not be part of the
Manufacturing Cost.
1.32 "MARKETING AUTHORIZATION" means, with respect to a country, the
regulatory authorization required to market and sell a Product in such country.
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-5-
1.33 "MGH LICENSE AGREEMENT" means the agreement between The General
Hospital Corporation d/b/a Massachusetts General Hospital ("MGH") and
Xxxxxxx-Xxxxx Squibb Company that is currently being negotiated and that will be
entered into after the Effective Date, and as it may be modified or supplemented
after being entered into, under which BMS will be obligated to pay MGH a royalty
on the sales of Products.
1.34 "NDA" means a New Drug Application, as defined in the United States
Federal Food, Drug and Cosmetic Act and applicable regulations promulgated
thereunder as amended from time to time.
1.35 "NET SALES" means the [*] by the Royalty Paying Party, its Affiliates
or sublicensees for sales of Product in finished package form (ready for use by
the ultimate consumer) in the Territory to a Third Party, including, but not
limited to, sales to wholesalers or other customers typical in each country in
bona fide, arm's length transactions. In determining Net Sales, certain
deductions may be taken against [*] to the extent not reimbursed by a Third
Party. These allowable deductions are:
1.35.1 [*];
1.35.2 [*];
1.35.3 [*];
1.35.4 [*]; and
1.35.5 [*];
A "sale" of a Product is deemed to occur upon [*].
With respect to a Combination Product, Net Sales for such Combination Product
sold by the Royalty Paying Party shall be determined [*].
1.36 "PHASE II CLINICAL STUDY" means a clinical study of a Product in human
subjects for the purpose of identifying a dose or doses at which there is
evidence of
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-6-
efficacy and acceptable safety and tolerability, which shall be deemed commenced
upon the dosing of the first subject in such study.
1.37 "PHASE III CLINICAL STUDY" means a clinical study of a Product in
human subjects the results of which could be used to establish safety and
efficacy of the Product as a basis for Marketing Authorization of the Product
which shall be deemed commenced upon the dosing of the first subject in such
study.
1.38 "PRODUCT" means any product or pharmaceutical formulation containing a
Compound as one of its active ingredients (or as the sole active ingredient), in
all dosage forms, formulations, presentations, line extensions, and package
configurations.
1.39 "REGULATORY AUTHORITY" means any regulatory agency or other
governmental instrumentality that has regulatory authority, anywhere or at any
governmental level, in the Territory over the Development or Commercialization
of the Products.
1.40 "ROYALTY PAYING PARTY" has the meaning set forth in Section 8.5.
1.41 "ROYALTY RECEIVING PARTY" has the meaning set forth in Section 8.5.
1.42 "BMS OPTION" has the meaning set forth in Section 3.2.1.
1.43 "BMS OPTION PERIOD" has the meaning set forth in Section 3.2.1.
1.44 "SOLE INVENTIONS" has the meaning set forth in Section 10.1.
1.45 "SUPPLY AGREEMENT" has the meaning set forth in Section 7.3.
1.46 "TERRITORY" means any country in the world.
1.47 "THIRD PARTY" means any business entity other than Vanda, BMS and
their respective Affiliates.
1.48 "VALID CLAIM" means a claim of an issued and unexpired patent, or a
claim of a pending patent application or a supplementary protection certificate,
which claim has not been held invalid or unenforceable by a court or other
government agency of competent jurisdiction from which no appeal can be or has
been taken and has not been held or admitted to be invalid or unenforceable
through re-examination or disclaimer, opposition procedure, nullity suit or
otherwise, which claim, but for the licenses granted herein, would be infringed
by the sale of a Product; provide however, that if a claim of a pending patent
application shall not have issued within [*] after the filing date from which
such claim takes priority, such claim shall not constitute a Valid Claim for the
purposes of this Agreement unless and until such claim shall issue.
1.49 "VANDA THIRD PARTY DEVELOPMENT OPTION" has the meaning set forth in
Section 3.1.1.
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-7-
1.50 "VANDA THIRD PARTY DEVELOPMENT OPTION PERIOD" has the meaning set
forth in Section 3.1.1.
ARTICLE 2
LICENSE GRANT
2.1 EXCLUSIVE LICENSE GRANT. Subject to all of the terms and conditions in
this Agreement, BMS hereby grants to Vanda a non-transferable, exclusive
license, with the limited right to sublicense pursuant to Section 2.3, under the
BMS Compound Patent Rights solely to the extent necessary to Develop, make, have
made, use, import, offer to sell, and Commercialize the Products in the Field in
the Territory.
2.2 NON EXCLUSIVE LICENSE GRANT. Subject to all of the terms and conditions
in this Agreement, BMS hereby grants to Vanda a non-transferable, nonexclusive
license, with the limited right to sublicense pursuant to Section 2.3, (a) under
the BMS Know How solely to the extent necessary to Develop, make, have made,
use, import, offer to sell, and Commercialize the Products in the Field in the
Territory, and (b) in the event Vanda enters into a Supply Agreement with a
Third Party in accordance with Article 7, under the BMS Manufacturing Patents
solely to the extent necessary to have made the Products or Compounds in the
Field in the Territory for sale to Vanda.
2.3 SUBLICENSE. The rights licensed to Vanda under Sections 2.1, 2.2(a) and
2.2(b) shall be sublicensable only as part of a license of rights to a Product
in the Field and only for use with such Product, and only where (i) the
sublicensee has agreed first in writing to be bound by the terms and conditions
of this Agreement in the same manner as Vanda, (ii) BMS is made an express third
party beneficiary of the sublicensee's obligations under such sublicense that
relate to compliance with the terms and conditions of this Agreement, and (iii)
a copy of the proposed sublicense shall have been provided to BMS for review
(financial terms not relating to this Agreement may be redacted). A copy of the
sublicense shall be provided to BMS promptly after execution. Vanda shall remain
jointly and severally liable with any such sublicensee for any failure by such
sublicensee to perform or observe the terms and conditions of this Agreement.
Each sublicense granted by Vanda to any right licensed to it hereunder shall
terminate immediately upon the termination of the license from BMS to Vanda with
respect to such right.
2.4 NO TRADEMARK LICENSE. No right or license, express or implied, is
granted to Vanda to use any trademarks, tradenames or trade dress owned or
Controlled by BMS and its Affiliates.
2.5 NO IMPLIED LICENSES. Only licenses and rights granted expressly herein
shall be of legal force and effect. No license or other right shall be created
hereunder by implication, estoppel or otherwise. Vanda represents, covenants and
warrants that it will use the rights licensed to it hereunder solely in
accordance with the terms and conditions contained in this Agreement.
-8-
2.6 MARKETING ARRANGEMENTS. In connection with arrangements with Third
Parties whereby such Third Parties would distribute or otherwise Commercialize
Products, Vanda agrees to comply and to cause such Third Parties to comply with
all terms and conditions of this Agreement.
2.7 RETAINED RIGHTS. All rights not expressly granted hereunder are
reserved by BMS and may be used by BMS for any purpose.
ARTICLE 3
OPTION GRANTS
3.1 VANDA'S OPTION. THIRD PARTY DEVELOPMENT PARTNERS.
3.1.1 Vanda Development Option Period. Vanda will have the right,
anytime prior to [*] ("Vanda Third Party Development Option Period"), to
negotiate an agreement to sublicense Vanda's rights to Develop and Commercialize
a Product (a "Development and Commercialization Agreement") with a Third Party
in at least one Major Market Country ("Vanda Third Party Development Option");
provided, however, that with respect to each Product,[*] Vanda shall have a
limited time in which to exercise the Vanda Third Party Development Option for
the Product before the right to exercise such option is suspended. Vanda shall
have [*] from the [*] to exercise such option. If Vanda exercises such option
during such [*] period, BMS shall have a right of first negotiation to enter
into a Development and Commercialization Agreement for the Product with Vanda.
[*] Vanda shall timely provide BMS with copies of any reports, data, results or
information, material to the Development of the Product that are or may become
available, including but not limited to [*]. BMS will have a [*] period of
exclusivity in which to negotiate and execute a Development and
Commercialization Agreement, and Vanda shall negotiate in good faith during such
[*] period. During such [*] period and such [*] period of exclusivity, Vanda
shall not approach any Third Party concerning a Development and
Commercialization Agreement or disclose [*]. If, [*] BMS does not [*] during
such [*] period of exclusivity, then Vanda shall have [*] from the end of the
[*] review period if BMS does not provide Vanda with [*]
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-9-
during such [*] period, or [*] for the Product or [*] from the end of the [*]
period of exclusivity if BMS [*] but the parties do not enter into a such an
agreement during such [*] period, as the case may be, to negotiate and enter
into a Development and Commercialization Agreement with a Third Party for the
Product. If Vanda does not enter into such an agreement with a Third Party
during such [*] period, then the Vanda Third Party Development Option shall be
suspended from the end of such [*] period (the Option Suspension Date) until
the end of the BMS Option Period for the Product. The Vanda Third Party
Development Option is exercisable by written notice from Vanda to BMS of
Vanda's intention to seek a Third Party partner. Such option shall be
exercisable on a [*] basis. For the avoidance of doubt, [*] shall be referred
to as the "Remaining Countries."
3.1.2 Option Exercise. Except as provided in Section 3.1.1 for the
period following the [*], in the event that Vanda exercises its Vanda Third
Party Development Option for a Product in a particular Major Market Country in
the Vanda Third Party Development Option Period, BMS shall have a right of first
negotiation to enter into a Development and Commercialization Agreement for that
Product in that Major Market Country. BMS shall have a [*] period, from the
receipt of Vanda's written notice to seek a Third Party partner, to elect to
enter into negotiations with Vanda. During the [*] review period, Vanda shall
timely provide BMS with copies of any reports, data, results or information,
material to the Development of a Product that are or may become available.
Thereafter BMS will have a [*] period of exclusivity in which to negotiate and
execute a Development and Commercialization Agreement for the Product, and Vanda
shall negotiate in good faith during such [*] period. If during the [*] review
period BMS [*] or if BMS does not enter into such an agreement during the [*]
period of exclusivity, then Vanda may enter into a Development and
Commercialization Agreement for the Product with a Third Party. The Parties will
use reasonable efforts to make decisions earlier than the final day of each
period allowed by this section 3.1.2 to the extent practicable. In the event
that Vanda enters into one or more Development and Commercialization Agreements
for a Product pursuant to the provisions of Section 3.1.1 and/or this Section
3.1.2 prior to the Option Suspension Date, then BMS will [*].
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-10-
3.1.3 Vanda Third Party Development Option Not Exercised. In the event
Vanda does not exercise its Vanda Third Party Development Option for a Product
or enter into any Development and Commercialization Agreements for the
Product/prior to [*] then BMS will have an opportunity to exercise its BMS
Option for the Product in all countries on the terms and conditions described in
Section 3.2.
3.2 BMS OPTION EXERCISABLE UPON COMPLETION OF PHASE III CLINICAL STUDIES:
COMMERCIALIZATION.
3.2.1 BMS Option Period. The BMS Option Period for a Product will
commence for the Remaining Countries (providing Vanda has not entered into one
or more Development and Commercialization Agreements for the Product which when
taken together include all of the Major Market Countries prior to the Option
Suspension Date for the product) on the date that (1) [*] and (2) [*]. The BMS
Option Period shall terminate [*] later ("BMS Option Period"). At any time
during the BMS Option Period, BMS may provide Vanda with written notice that
either: (a) it does not wish to Develop or Commercialize the Product in the
Remaining Countries; or (b) it wishes to reacquire all rights to the Product in
the Remaining Countries ((b) shall be referred to as the "BMS Option"). [*] For
the avoidance of doubt, if BMS does not exercise the BMS Option for the
Remaining Countries within the BMS Option Period, then upon completion of the
BMS Option Period, the Vanda Third Party Development Option shall be exercisable
for the Remaining Countries for the remainder of the Vanda Third Party
Development Option Period.
3.2.2 BMS Option Diligence Materials. Vanda shall provide to BMS on or
prior to the commencement of the BMS Option Period, any additional data
(including without limitation, copies of all case report forms, if requested by
BMS) or information relating to the Development of the Product that is in
Vanda's possession which BMS reasonably believes to be necessary or useful for
its review of the opportunity. At [*] intervals during the BMS Option Period,
Vanda will promptly provide any reports, data, results or information, material
to the Development of a Product that may become available.
3.2.3 Option Exercised. In the event BMS exercises its BMS Option for
a Product, then, among other things,
(a) LICENSE GRANT. The licenses granted to Vanda pursuant to
Section 2.1 and 2.2 will immediately terminate with respect to the Product in
the Remaining Countries without further action on the part of either Party, and
Vanda shall cease all use of the BMS Patent Rights, and BMS Know-How with
respect to the Product in the Remaining Countries;
----------
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-11-
(b) TRANSFER OF DATA, INFORMATION AND REGULATORY FILINGS. Vanda
shall promptly assign to BMS all rights, title and interests in any INDs,
Marketing Authorizations, and Approvals that it shall have filed in the
Remaining Countries with respect to the Product and the Compound contained in
the Product and all data generated by it with respect to the Product and the
Compound contained in the Product in the Remaining Countries, and will promptly
transfer to BMS originals or copies of all pertinent documents relating to same
as requested by BMS. In the event that Vanda fails to effectuate the transfer of
the foregoing within [*] after the date that BMS exercises its BMS Option, then,
in addition to any other recourse or remedy that BMS may be entitled to at law
or in equity, BMS shall [*]. BMS will reimburse Vanda for any out-of-pocket
expenses incurred in connection with such assignment. Within [*] following any
such assignment to BMS, the Parties will finalize and enter into a Data Safety
Exchange covering such matters as adverse event reporting, data safety exchange
and response to physician inquiries so that BMS may fulfill its reporting
responsibilities on a timely basis to Regulatory Authorities;
(c) DEVELOPMENT BMS will thereafter be solely responsible for any
further Development activities needed to achieve Approvals in the Remaining
Countries for the Product, and will use Commercially Reasonable Efforts to
achieve same;
(d) COMMERCIALIZATION. Provided the United States is included in
the Remaining Countries, as soon as reasonably necessary, and in no event later
than [*], BMS will advise Vanda in writing whether it intends to seek a
co-promotion partner in the United States for the Product. In the event that BMS
seeks a co-promotion partner in the United States, and provided that Vanda is
able to meet the requirements established by BMS at that time for a co-promotion
partner, the Parties will have [*] in which to negotiate a mutually acceptable
co-promotion agreement in accordance with Section 3.3; and
(e) OTHER TERMS. The provisions of Section 13.4. l(e), (g), (h)
and (i) shall also apply as though set forth herein. It is understood and agreed
that BMS shall [*].
3.2.4 BMS Option Not Exercised. In the event that BMS does not
exercise its BMS Option for a Product with respect to the Remaining Countries,
Vanda will, subject to Section 3.3, Develop and Commercialize the Product in the
Remaining Countries pursuant to the terms and conditions set forth in this
Agreement.
3.3 RIGHT OF FIRST NEGOTIATION TO ACT AS A CO-PROMOTION PARTNER IN
COMMERCIALIZATION OF A PRODUCT BY EITHER PARTY.
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-12-
3.3.1 Vanda's Right to Co-Promote. If BMS is Developing and/or
Commercializing a Product in the U.S. pursuant to this Agreement and decides to
co-promote the Product with a Third Party marketing partner in the U.S., BMS
shall promptly notify Vanda in writing of its intention to co-promote the
Product with such Third Party marketing partner in the U.S. Vanda will have [*]
from the date BMS notifies Vanda of its intention to co-promote the Product with
such Third Party marketing partner to provide written notice of its intent to
exercise its option to co-promote the Product with BMS in the U.S. and
demonstrate that it has, or is reasonably likely to have at the time required,
the capabilities to undertake such co-promotion effort, including without
limitation, sufficient numbers of Vanda employees with sufficient experience as
sales representatives and sales and marketing managers and executives to allow
it to fulfill the obligations established by BMS for the co-promotion partner
(including without limitation minimum number of details, minimum primary detail
equivalents, sales force size and training, advertising and promotional spend
requirements, etc.). Vanda may not delegate or subcontract such co-promotion
responsibilities to a Third Party, unless such Third Party (a) has been an
alliance partner of Vanda's for at least [*] prior to the date Vanda receives
notice under this Section 3.2.1 from BMS of BMS' intention to co-promote the
Product with a Third Party marketing partner, and (b) has the capabilities to
undertake such co-promotion effort, including without limitation, sufficient
numbers of employees with sufficient experience as sales representatives and
sales and marketing managers and executives to allow it to fulfill the
obligations established by BMS for the co-promotion partner (including without
limitation minimum number of details, minimum primary detail equivalents, sales
force size and training, advertising and promotional spend requirements, etc.).
If Vanda exercises its option and demonstrates to BMS' satisfaction that it can
meet, or is reasonably likely to be able to meet at the necessary time, such
capabilities and fulfill such obligations by itself or with such an alliance
partner, the Parties will, for a period not longer than [*] after Vanda's
exercise of the option, exclusively negotiate with each other in good faith a
Co-Promotion Agreement on commercially reasonable terms and conditions [*]. If
after such [*] period, the Parties have not entered into a co-promotion
agreement, BMS would be free to enter into an arrangement with a Third Party
marketing partner.
3.3.2 BMS' Right to Co-Promote. If Vanda is Commercializing a Product
pursuant to this Agreement and decides to co-promote the Product with a Third
Party marketing partner, Vanda shall promptly notify BMS in writing of its
intention to co-promote the Products with such Third Party marketing partner.
BMS will have [*] from the date Vanda notifies BMS of its intention to
co-promote the Product with such Third Party marketing partner to provide
written notice of its intent to exercise its option to co-promote the Product
with Vanda. If BMS exercises its option, the Parties will, for a period not
longer than [*] after BMS' exercise of the option, negotiate exclusively with
each other in good faith a co-promotion agreement on commercially reasonable
terms and conditions [*]. If after such [*] period, the Parties have not entered
into a co-promotion agreement, Vanda would be free to enter into an arrangement
with a Third Party marketing partner.
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-13-
3.4 RESPONSIBILITIES REGULATORY AFFAIRS. Following the date that the IND,
Marketing Authorization or Approval in a given country for a Product has been
assigned to BMS, BMS shall have sole responsibility for preparing, all
regulatory filings and related submissions with respect to the Product and the
Compound contained in the Product in such country and making all final decisions
relating thereto. BMS shall be the primary interface with and otherwise handle
all interactions with Regulatory Authorities concerning the Product and the
Compound contained in the Product. Pursuant to Section 14.7, Vanda shall be
obliged to render whatever assistance BMS may reasonably request to allow BMS to
fulfill its obligations under this Section 3.4. To the extent not prohibited by
law or regulation, in the event that BMS is Developing and Commercializing a
Product in the United States, Vanda shall have the right to have one
representative participate in all material meetings pertaining to Development of
the Product between representatives of BMS and the FDA. BMS will provide Vanda,
at least five (5) business days before any such meeting, with copies of all
documents, correspondence and other materials in its possession which are
relevant to the matters to be addressed at any such meeting. BMS will provide
Vanda with draft and final copies (which may be wholly or partly in electronic
form) of all material correspondence with the Regulatory Authorities in each of
the Major Market Countries relating to the Product, including any draft
Marketing Authorizations and Approvals, for Vanda's review and comment within a
reasonable time prior to filing with the appropriate Regulatory Authority. BMS
shall give due consideration to Vanda's comments, however, BMS shall not-be
bound thereby.
ARTICLE 4
TRANSFER OF BMS KNOW-HOW;
4.1 TRANSFER OF BMS COMPOUND KNOW-HOW.
4.1.1 TRANSFER. During the [*] period following the Effective Date,
BMS shall provide Vanda with the assistance of certain BMS employees having
knowledge relevant to the Compounds to provide Vanda with a reasonable level of
technical assistance and consultation in connection with the transfer of BMS
Know-How (provided that BMS shall only be required to make a good faith effort
to provide the BMS Know How but shall not be in default hereunder for
inadvertent failure to disclose all or non-material information). Vanda shall be
responsible for ensuring that its personnel who receive such assistance are
appropriately qualified and experienced for such purpose.
4.1.2 COPIES OF DOCUMENTS. BMS shall provide Vanda with one copy of
all documents, data or other information Controlled by BMS to the extent that
such documents, data and information are the subject of the BMS Know-How
licenses and are, in BMS' good faith judgment, reasonably necessary for the
Development, manufacture or Commercialization of the Compounds and are
reasonably available to BMS without undue searching; provided however, the
foregoing shall in no event require BMS to provide copies of laboratory
notebooks or manufacturing run records required to be maintained by FDA. The BMS
Know-How provided by BMS shall not be used by Vanda for any purpose other than
Development, manufacture or Commercialization of
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-14-
the Compounds and Products and is Confidential Information of BMS. Vanda shall
assume full responsibility and liability to BMS for any unauthorized use or
disclosure of Confidential Information of BMS. BMS shall be responsible for the
cost of providing one set of copies only, and in addition to paper and other
tangible copies, BMS shall, upon Vanda's request and where already available to
BMS, also provide to Vanda electronic copies of such documents, data and other
information, provided, that BMS shall have no obligation to reformat or
otherwise alter or modify any such materials in order to provide them to Vanda.
4.1.3 ON-SITE CONSULTING. BMS shall not be obligated to provide more
than [*] of consulting advice or on-site consulting advice (including travel
time) over the term of this Agreement, as may be requested by Vanda, with
respect to the transfer of any BMS Know-How. BMS will be reimbursed by Vanda for
[*]. In the event that Vanda requires consultation with BMS over and above the
[*] provided here, Vanda will submit its request for consultation to BMS, in
writing, stating in sufficient detail the subject matter, and the number of
hours required. BMS will consider each such request in good faith, and will
inform Vanda in a timely manner if BMS will be able to provide the consulting
time requested, with the understanding that BMS shall not obligated to provide
more than [*] consulting advice or on-site consulting advice (including travel
time) over the term of this Agreement.
4.1.4 IND. As soon as reasonable practicable after the Effective Date,
BMS will promptly effectuate the assignment of IND 54,776 (the active IND for
the Compound currently identified as BMS-214778) to Vanda. Vanda will [*].
4.2 NON-SOLICITATION. During the term of this Agreement, and for [*]
thereafter, each Party and its Affiliates shall not solicit, directly or
indirectly, any employee of the other Party or of an Affiliate of the other
Party, wherever located, who is or was involved in the performance of this
Agreement; provided, that the foregoing restriction on solicitation shall not
apply to advertisements run in trade journals or other publications or on the
Internet that are targeted to qualified individuals generally for the position
in question.
ARTICLE 5
DEVELOPMENT
5.1 PROGRAM LIAISON. As soon as practicable after the Effective Date, each
Party will provide the other, in writing, with the name of its "Program
Liaison." The Program Liaison will act as the primary liaison in coordinating
the activities under this Agreement. The Program Liaisons will review and agree
on the suitability of the Development Plan set forth in Schedule 1.19. Before
Vanda begins Development of a Product under a Development Plan other than the
Development Plan in Schedule 1.19, the Program Liaisons will prepare such
Development Plan, and the Parties must agree in
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-15-
writing upon such Development Plan before Vanda commences Development of the
Product under such Development Plan.
5.2 DEVELOPMENT
5.2.1 Vanda shall use good faith Commercially Reasonable Efforts to
Develop the Compounds and Products.
5.2.2 As soon as reasonably practicable after the Effective Date,
Vanda shall commence Phase II Clinical Studies for the Product in accordance
with the Development Plan set forth in Schedule 1.19 and this Agreement. In any
event, Vanda (a) [*], (b) [*], (c) [*], (d) [*]. In the event that any of such
milestones are missed, it shall be deemed a material breach of this Agreement
for the purposes of Article 13. BMS' ability to terminate this Agreement
pursuant to Section 13.2 shall apply [*]. If Vanda misses any of the above
milestone dates, Vanda may request that BMS grant a reasonable extension to
allow it to meet such milestone, and BMS agrees that it will not unreasonably
withhold its assent to any such reasonable revision where supported by clear
evidence that Vanda has been making good faith and diligent efforts to achieve
the milestones but has failed as a result of technical difficulties or delays
that the parties could not have reasonably avoided in the achievement of such
milestones; and provided, that BMS may also need to seek approval of MGH in such
event, and any approval by BMS shall further be conditioned on receipt of
approval of MGH.
5.3 DEVELOPMENT REPORTS. Vanda shall provide [*] written reports to BMS,
within [*], presenting a meaningful summary of the Development activities
accomplished by Vanda and results obtained through [*]. Such reports shall
include all material results, information and data generated in the course of
Development of Products. Vanda will make Development plans, clinical protocols,
investigator brochures and regulatory submissions available to BMS at
BMS' written request. In addition, on reasonable request by BMS, Vanda will meet
with BMS to make presentations of the Development activities taken relating to
the Products.
5.4 RECORDS. Vanda shall maintain complete and accurate records of all work
conducted in furtherance of the Development and Commercialization of the
Compounds and Products and all results, data and developments made in
furtherance thereof. Such records shall be complete and accurate and shall fully
and properly reflect all work done and results achieved in sufficient detail and
in good scientific manner appropriate for patent and regulatory purposes.
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-16-
5.5 DEVELOPMENT RESPONSIBILITIES AND COSTS. Except in the case where BMS
enters into a Development and Commercialization Agreement or exercises its BMS
Option, Vanda shall have sole responsibility for, and shall [*] of conducting,
Development with respect to Products and Compounds. Vanda shall Develop the
Compounds and Products in compliance with all applicable legal and regulatory
requirements, including without limitation all legal and regulatory requirements
pertaining to the design and conduct of clinical studies.
5.6 REGULATORY RESPONSIBILITIES AND COSTS.
5.6.1 Regulatory Interactions. Only in the case where Vanda does not
enter into any Development and Commercialization Agreements and BMS does not
exercise the BMS Option, Vanda shall have sole responsibility for, and shall
bear the cost of preparing, all regulatory filings and related submissions with
respect to Compounds or Products. Vanda shall be the primary interface with and
otherwise handle all interactions with Regulatory Authorities concerning
Compounds or Products. To the extent not prohibited by law or regulation, BMS
shall have the right to have one representative participate in all material
meetings pertaining to Development of a Product between representatives of Vanda
and Regulatory Authorities of the Major Market Countries and the FDA. Vanda will
provide BMS, at least five (5) business days before any such meeting, with
copies of all documents, correspondence and other materials in its possession
which are relevant to the matters to be addressed at any such meeting. Vanda
will provide BMS with draft and final copies (which may be wholly or partly in
electronic form) of all material correspondence with Regulatory Authorities
relating to the Product, including any draft Marketing Authorizations, for BMS'
review and comment within a reasonable time prior to filing with the Regulatory
Authorities. Vanda will be responsible for meeting the requirements of all
pre-approval inspections required by any Regulatory Authorities.
5.6.2 Ownership of Regulatory Filings. Vanda shall own all INDs,
Marketing Authorizations, Approvals and submissions in connection therewith and
Approvals shall be obtained by and in the name of Vanda, unless and until BMS
(a) has entered into a Development and Commercialization Agreement with Vanda
pursuant to Section 3.1, or (b) has exercised the BMS Option.
ARTICLE 6
COMMERCIALIZATION
6.1 COMMERCIALIZING PARTY'S RESPONSIBILITIES.
6.1.1 Introduction. The Party Commercializing a Product in a country
(the "Commercializing Party") shall use Commercially Reasonable Efforts to
Commercialize the Product and, at a minimum, effect introduction of the Product
into such country as soon as reasonably practicable.
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-17-
6.1.2 Continued Availability. Following the First Commercial Sale of a
Product in a country in the Territory and until the expiration or termination of
this Agreement, the Commercializing Party shall use Commercially Reasonable
Efforts to supply and keep the Product reasonably available to the public in
such country.
6.1.3 Marking. Each Product Commercialized by Vanda under this
Agreement shall be marked (to the extent not prohibited by law): (a) with a
notice that such Product is sold under a license from BMS and (b) with all
patent and other intellectual property notices relating to the BMS Patent Rights
in such a manner as may be required by applicable law.
ARTICLE 7
MANUFACTURE AND SUPPLY
7.1 RESPONSIBILITY. Subject to Section 7.2, the Commercializing Party for a
Product shall be solely responsible at its expense for all of its requirements
in the Territory for any purpose of the Product and the Compound contained in
the Product and shall use Commercially Reasonable Efforts to supply all
requirements of its customers. The Commercializing Party shall manufacture, or
cause to have manufactured, the Product and the Compound contained in the
Product in compliance with all applicable legal and regulatory requirements and
with its internal policies and procedures.
7.2 PROVISION OF COMPOUND. As soon as possible after the Effective Date,
(and no later than thirty (30) days) BMS will transfer to Vanda [*]active
pharmaceutical ingredient that has been requalified by BMS to be within
specification as well as the most recent reference standard that has been
submitted.
7.3 RIGHT TO MANUFACTURE COMMERCIAL SUPPLY. In the event that BMS has
entered into a Development and Commercialization Agreement or exercised its BMS
Option for a particular Product, BMS will have the first right to manufacture
and supply such Product or the Compound contained in such Product at any time
thereafter for clinical and commercial use, as applicable. In the event that BMS
does not enter into a Development and Commercialization Agreement or exercise
its BMS Option for a particular Product, and Vanda enters into negotiations with
a Third Party to manufacture a clinical or commercial supply of such Product or
the Compound contained in such Product (the "Supply Agreement"), it will
promptly notify BMS and provide [*]. BMS will have [*] from receipt of the data
summary to notify Vanda that it will [*]. The Parties will then negotiate a
Supply Agreement in good faith for [*] or such longer period as agreed between
the Parties. In the event the Parties do not enter into a Supply Agreement
within such [*] period, or the agreed extension thereof, Vanda is free to enter
into an agreement with any other entity with respect to such clinical or
commercial supply.
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-18-
ARTICLE 8
PAYMENTS
8.1 TECHNOLOGY ACCESS FEE. On [*], Vanda will pay to BMS the sum of five
hundred thousand Dollars ($500,000) as partial reimbursement for BMS' previously
incurred research and development expenses for the Compounds.
8.2 MILESTONE PAYMENTS.
8.2.1 Milestone Payments By Vanda. In the event that Vanda is
Developing or Commercializing a Product in any country and/or has entered into a
Development and Commercialization Agreement for the Product with a Third Party,
then Vanda will pay BMS, as partial reimbursement for research and development
expenses for the Compounds, upon Vanda or such Third Party achieving the
following milestones for that Product:
MILESTONE DOLLARS
--------- -------
[*] [*]
[*] [*]
[*] [*]
[*] [*]
8-2.2 "BMS Option" Milestone Payments by BMS. In the event that BMS
exercises its BMS Option for a particular Product, then BMS will pay Vanda, as
partial reimbursement for research and development expenses for the Compounds,
upon BMS achieving the following milestones for that Product:
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-19-
MILESTONE DOLLARS
--------- -------
[*] [*]
[*] [*]
[*] [*]
8.2.3 [*]
8.3 TIMING. Payment shall be made [*] following the occurrence of an event
giving rise to a payment obligation hereunder. All payments to BMS shall be made
by wire transfer in Dollars to the credit of the bank account indicated below or
to such other account as may be designated, from time to time, by BMS in
writing. All Payments to Vanda shall be made by wire transfer in Dollars to the
credit of such bank account as may be designated, from time to time, by Vanda in
writing.
Bank: [*]
ABA No.: [*]
Account No.: [*]
Account Name: [*]
Company Details: [*]
8.4 DEVELOPMENT COSTS.
8.4.1 Vanda Development Costs. Vanda will be responsible for all
Development Costs, unless BMS enters into a Development and Commercialization
Agreement prior to the BMS Option Period, in which the terms may involve sharing
in Development Costs for that Product.
8.5 ROYALTY PAYMENT.
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-20-
8.5.1 Vanda Royalty to BMS. In the event that Vanda Commercializes a
Product and/or enters into a Development and Commerdalization Agreement with a
Third Party for the Product, then Vanda will pay BMS a [*] percent ([*]%)
royalty on annual Net Sales of that Product by Vanda, its Affiliates, and
sublicensees, including but not limited to such Third Party, in the Territory.
In the event that Vanda enters into one or more Development and
Commercialization Agreements for a particular Product, Vanda will also pay BMS
[*] percent ([*]%) of [*] that are received by Vanda in consideration of each
such Development and Commercialization Agreement. Vanda agrees that it shall
also pay MGH, on behalf of BMS, all financial obligations of BMS under the MGH
License Agreement arising from the Development, manufacture and
Commercialization of Products by Vanda, its Affiliates and sublicensees,
including but not limited to any royalty obligation under the MGH license
Agreement arising from the sale of any Product by Vanda, its Affiliates or
sublicensees in the Territory, and shall comply with and fulfill all applicable
terms and conditions of the MGH License Agreement. Without limiting the
foregoing, with respect to each Product, Vanda shall comply with and fulfill all
of the applicable terms and conditions of the MGH License Agreement relating to
the Development, manufacture and Commercialization of Products by Vanda, its
Affiliates and sublicensees, which shall include making the royalty payments in
accordance with the terms and conditions of the MGH license Agreement, keeping
books of accounting and making them available for inspection by MGH in
accordance with the terms and conditions of the MGH License Agreement, providing
any information and reports to MGH required by the terms and conditions of the
MGH License Agreement in connection with the sale of any Product, and obtaining
and maintaining the type and amounts of insurance required of BMS under the MGH
License Agreement. Vanda shall provide BMS with a copy of each document provided
to MGH in accordance with the terms and conditions of the MGH License Agreement,
including but not limited to a copy of each royalty report and a copy of any
other document providing information to MGH.
8.5.2 BMS Royalty to vanda. In the event that BMS exercises its BMS
Option for a particular Product, BMS will pay directly to Vanda a [*] percent
([*]%)royalty on annual Net Sales of that Product by BMS, its Affiliates and
sublicensees in the Remaining Countries. If, however, BMS entered into a
Development and Commercialization Agreement, BMS would pay [*].
Each of the foregoing shall be collectively and individually referred to as
"Royalties." The Party paying Royalties shall be referred to as the "Royalty
Paying Party". The Party receiving Royalty payments shall be referred to as the
"Royalty Receiving Party".
8.6 THIRD PARTY ROYALTY PAYMENTS. The Royalty Paying Party shall be
responsible for making any Third Party license payments, whether existing as of
or arising after the Effective Date and reasonably necessary to Develop or
Commercialize the Product.
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-21-
8.7 [*] THIRD PARTY ROYALTY PAYMENTS. Other than any royalties due to a
Third Party under the MGH License Agreement or under agreements existing as of
the Effective Date with respect to the manufacture, use or sale of a Product,
the Royalty paying party, its Affiliates and sublicensees shall, except where
Section 8.8.2 applies, be entitled to offset up to [*] of any royalties due to
the Royalty Receiving Party by the amount of any royalties and license fees paid
to a Third Party reasonably necessary to enable the Royalty Paying Party to sell
the Product in a country in the Territory; provided, that the royalty payable
to the Royalty Receiving Party shall not be reduced below [*] of what it would
otherwise have received in the absence of this Section 8.7.
8.8 TERM FOR ROYALTY PAYMENTS.
8.8.1 Term. Royalties shall be payable on a country by country basis
from the First Commercial Sale until the later of (a) [*] from the First
Commercial Sale and (b) the expiration of the last to expire patent owned or
Controlled by the Royalty Receiving Party (including extensions thereof) with a
Valid Claim directed to the Product, including, without limitation, a method of
use thereof.
8.8.2 Countries With No Valid Claim Covering Product. If at any time
during the royalty period set forth in 8.8.1 there is in a country no patent
owned or Controlled by the Royalty Receiving Party with a Valid Claim directed
to the Product or a method of use thereof, then the royalties shall be reduced
[*] with respect to the Net Sales of the Product in such country.
8.9 SALES REPORTS
8.9.1 Substance of Reports. After the First Commercial Sale of Product
and during the term of this Agreement, the Royalty Paying Party shall furnish or
cause to be furnished to the Royalty Receiving Party a written report, within 30
days after the end of each calendar quarter, showing the amount of royalty due
calculated for such calendar quarter, with the royalty due paid to the Royalty
Receiving Party at the time such report is provided. With each quarterly
payment, the Royalty Paying Party shall deliver to the Royalty Receiving Party a
full and accurate accounting to include at least the following information:
(a) Quantity of each Product sold or leased (by country) by the
Royalty Paying Party, and its Affiliates or sublicensees;
(b) Total xxxxxxxx for each Product (by country);
(c) Quantities of each Product used by the Royalty Paying Party
and its Affiliates or sublicensees or sold to the U.S. Government;
(d) Names and Addresses of all sublicensees of the Royalty Paying
Party; and
(e) Total royalties payable to the Royalty Receiving Party.
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-22-
8.9.2 Sales Record Audit. The Royalty Paying Party shall keep, and
shall cause each of its Affiliates and sublicensees, if any, to keep full and
accurate books of accounting containing all particulars that may be necessary
for the purpose of calculating all royalties payable to the Royalty Receiving
Party. Such books of accounting shall be kept at their principal place of
business and, with all necessary supporting data, shall during all reasonable
times for the [*] next following the end of the calendar year to which each
shall pertain, be open for inspection at reasonable times by an independent
certified accountant selected by the Royalty Receiving Party, and as to which
the Royalty Paying Party has no reasonable objection, at the Royalty Receiving
Party's expenses, for the purpose of verifying royalty statements for compliance
with this Agreement. Such accountant must have agreed in writing to maintain all
information learned in confidence, except as necessary to disclose to the
Royalty Receiving Party such compliance or noncompliance by the Royalty Paying
Party. The results of each inspection, if any, shall be binding on both Parties.
The Royalty Receiving Party shall pay for such inspections, except that in the
event there is any upward adjustment in aggregate royalties payable for any year
shown by such inspection of more than [*] of the amount paid, the Royalty Paying
Party shall pay for such inspection. Any overpayments shall [*].
8.10 CURRENCY EXCHANGE. With respect to Net Sales invoiced in Dollars, the
Net Sales and the amounts due to the Royalty Receiving Party hereunder shall be
expressed in Dollars. With respect to Net Sales invoiced in a currency other
than Dollars, the Net Sales shall be expressed in the domestic currency of the
entity making the sale, together with the Dollar equivalent, calculated using
the arithmetic average of the spot rates on the close of business on last
Business Day of each month of the calendar quarter in which the Net Sales were
made. The "closing mid-point rates" found in the "dollar spot forward against
the dollar" table published by The Financial Times" or any other publication as
agreed to by the Parties shall be used as the source of spot rates to calculate
the average as defined in the preceding sentence. All payments shall be made in
Dollars. If at any time legal restrictions in any country in the Territory
prevent the prompt remittance of any payments with respect to sales in that
country, the Royalty Paying Party shall have the right and option to make such
payments by depositing the amount thereof in local currency to the Royalty
Receiving Party's account in a bank or depository in such country.
8.11 TAX WITHHOLDING. The withholding tax, duties, and other levies (if
any) applied by a government of any country of the Territory on payments made by
the Royalty Paying Party, to the Royalty Receiving Party hereunder shall be
borne by the Royalty Receiving Party. The Royalty Paying Party, its Affiliates
and sublicensees shall cooperate with the Royalty Receiving Party to enable the
Royalty Receiving Party to claim exemption therefrom under any double taxation
or similar agreement in force and shall provide to the Royalty Receiving Party
proper evidence of payments of withholding tax and assist the Royalty Receiving
Party by obtaining or providing in as far as possible the required documentation
for the purpose of the Royalty Receiving Party' tax returns.
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-23-
8.12 INTEREST DUE. In case of any delay in payment by the Royalty Paying
Party to the Royalty Receiving Party not occasioned by Force Majeure, interest
on the overdue payment shall accrue [*], as determined for each month on the
last business day of that month, assessed from the day payment was initially
due. The foregoing interest shall be due from the Royalty Paying Party without
any special notice.
ARTICLE 9
REPRESENTATIONS AND WARRANTIES; DISCLAIMER; LIMITATION OF LIABILITY
9.1 MUTUAL WARRANTIES. Each Party represents and warrants to the other
Party that (a) it (and in the case of Vanda, its general partner as well) has
all requisite corporate power and authority to enter into this Agreement, to
grant the licenses granted by it hereunder, and to perform its other obligations
under this Agreement, (b) execution of this Agreement and the performance by the
warranting Party (and in the case of Vanda, by its general partner as well) of
its obligations hereunder, including, without limitation, the licenses granted
by that Party hereunder, have been duly authorized, (c) this Agreement is fully
binding and enforceable on each Party (and in the case of Vanda, on its general
partner as well) in accordance with its terms, and (d) the performance of this
Agreement by it does not create a breach or default under any other agreement to
which it (and in the case of Vanda, to which its general partner as well) is a
Party.
9.2 BMS WARRANTIES AND COVENANTS. As of the Effective Date, BMS represents
and warrants to Vanda that, to the actual knowledge of its in-house patent
counsel (based on such counsels' good faith understanding of the facts and
information in their possession without any duty to conduct any investigation
with respect to such facts and information), (a) there is no pending litigation
which alleges, or any written communication alleging, that BMS(1) activities
with respect to the BMS Patent Rights or the Compounds have infringed or
misappropriated any of the intellectual property rights of any Third Party, (b)
all fees required to be paid by BMS in order to maintain the patents licensed to
Vanda hereunder have been paid to date as of the Effective Date such that the
claims included in any such issued patents are in full force and effect as of
the Effective Date, (c) [*], (d) it has the full right, power and authority to
enter into this Agreement and to grant the licenses granted under Article II
hereof, (e) it has not previously assigned, transferred, conveyed or otherwise
encumbered its right, title and interest in the BMS Patent Rights or the BMS
Know-How, and (f) it is the sole and exclusive owner of the BMS Patent Rights
and the BMS Know-How.
9.3 VANDA WARRANTIES AND COVENANTS.
9.3.1 Vanda warrants, represents and covenants that all of its
activities related to its use of the BMS Patent Rights and BMS Know-How, and the
Development and Commercialization of the Compounds and Products, pursuant to
this Agreement shall comply in all material respects with all applicable legal
and regulatory requirements.
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-24-
Vanda further warrants and covenants that it shall not engage in any activities
that use the BMS Patent Rights and BMS Know-How in a manner that is outside the
scope of the license rights granted to it hereunder.
9.3.2 Vanda warrants, represents and covenants that it has [*]
9.4 DISCLAIMER. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, BMS MAKES
NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR
IMPLIED, INCLUDING ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE BMS PATENT RIGHTS OR BMS
KNOW-HOW OR ANY LICENSE GRANTED BY BMS HEREUNDER, OR WITH RESPECT TO ANY
COMPOUNDS OR PRODUCTS. FURTHERMORE, NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED
AS A WARRANTY THAT ANY PATENT OR OTHER PROPRIETARY RIGHTS INCLUDED IN THE BMS
PATENT RIGHTS ARE VALID OR ENFORCEABLE OR THAT VANDA'S USE OF THE BMS PATENT
RIGHTS AND BMS KNOW-HOW CONTEMPLATED HEREUNDER DOES NOT INFRINGE ANY PATENT
RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY.
9.5 LIMITATION OF LIABILITY. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR
OTHERWISE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER WITH RESPECT TO ANY
SUBJECT MATTER OF THIS AGREEMENT, WHETHER UNDER ANY CONTRACT, NEGLIGENCE, STRICT
LIABILITY, OR OTHER LEGAL OR EQUITABLE THEORY, FOR ANY INCIDENTAL, INDIRECT,
SPECIAL, EXEMPLARY, PUNITIVE, MULTIPLE, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT
NOT LIMITED TO, LOST PROFITS, LOSS OF USE, DAMAGE TO GOODWILL, OR LOSS OF
BUSINESS) AND, IN ANY CASE, BMS SHALL NOT BE LIABLE IN AN AMOUNT GREATER THAN
[*]; PROVIDED, THAT THE FOREGOING SHALL NOT APPLY TO ANY BREACH BY VANDA OF THE
RIGHTS LICENSED TO IT UNDER ARTICLE 2 HEREOF OR TO ANY BREACH BY A PARTY OF
ARTICLE 11 HEREOF.
ARTICLE 10
PATENT MAINTENANCE; INFRINGEMENT; CONFIDENTIALITY
10.1 INVENTIONS. Each Party shall own the entire right, title and interest
in and to any and all inventions conceived solely by its employees and agents
after the Effective Date ("Sole Inventions"), and any patents covering such Sole
Inventions. BMS and Vanda shall each own an undivided one-half interest in and
to any and all inventions conceived jointly after the Effective Date by (a)
employees and agents of BMS and (b) employees and agents of Vanda, and in and to
any patents and other intellectual property
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-25-
rights claiming or covering such joint Inventions ("Joint Inventions") BMS and
Vanda as joint owners each shall have the right to exploit and to grant licenses
under such Joint Inventions (without an accounting or obligation to, or consent
required from, the other Party), unless otherwise specified in this Agreement.
10.2 PATENT MAINTENANCE; ABANDONMENT.
10.2.1 BMS PATENT RIGHTS. [*] shall be responsible for, and shall
control, the prosecution (including any interferences, reissue proceedings and
reexaminations) and maintenance of all BMS Patent Rights. [*] shall provide [*]
with copies of all correspondence from any and all patent offices concerning the
BMS Patent Rights and an opportunity to comment on any proposed responses,
voluntary amendments and submissions of any kind to be made to any and all such
patent offices (other than routine filings and correspondence to maintain the
patents). [*] shall have the right to select the in-house or outside counsel who
will perform the aforementioned prosecution and maintenance-associated
activities, and [*] shall reimburse [*] (including any fees payable to the
applicable patent office) incurred in connection therewith. In the event that
BMS exercises the BMS Option and the Parties are co-Developing or co-promoting
the Product, [*] will only reimburse [*] for [*] incurred [*], as applicable. If
[*] elects not to pay any expenses with respect to a BMS Patent Right in a given
country, [*] shall inform [*] in writing not less than [*] before any relevant
deadline (or, in the event of a shorter period in which to respond to a patent
office, as soon as reasonable practicable). In the event [*] makes such
election, or if [*] fails to reimburse [*] for [*] incurred [*] a BMS Patent
Right in a given country, [*]. Except as provided in the previous sentence, [*]
may not abandon a BMS Patent Right without the prior written consent of [*].
10.2.2 SOLE INVENTIONS. Each Party shall direct and control at its
expense the filing, prosecution (including any interferences, reissue
proceedings and reexaminations) and maintenance of all patents covering its Sole
Inventions.
10.2.3 JOINT INVENTIONS. The Parties shall supervise, and shall
assign, on a Joint Invention-by-Joint Invention basis, one Party to be
responsible for, the filing, prosecution (including any interferences, reissue
proceedings and reexaminations) and maintenance of all patents covering such
Joint Invention consistent with such strategy. The designated controlling Party
shall provide the other Party with (a) drafts of any new patent application that
covers a Joint Invention prior to filing that application, allowing adequate
time for review and comment by the Party if possible; provided, however, the
designated controlling Party shall not be obligated to delay the filing of any
patent application; and (b) copies of all correspondence from any and all patent
offices concerning patent applications covering Joint Inventions and an
opportunity to comment on any proposed responses, voluntary amendments and
submissions of any kind to be
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-26-
made to any and all such patent offices. The Parties shall mutually agree on the
in-house or outside counsel who will perform the filing, prosecution and
maintenance of Joint Inventions and the allocation of out-of-pocket costs
incurred in connection therewith.
10.3 ENFORCEMENT OF BMS PATENT RIGHTS AGAINST INFRINGERS.
10.3.1 Enforcement [*]. In the event that BMS or in-house counsel
of Vanda becomes aware of a suspected infringement of any BMS Patent Right, such
Party shall notify the other Party promptly, and following such notification,
the Parties shall confer. [*] shall have the right, but shall not be obligated,
to bring an infringement action at its own expense, in its own name and entirely
under its own direction and control. [*] will reasonably assist [*] in any
action or proceeding being prosecuted if so requested, and will lend its name to
such actions or proceedings if requested by [*] or required by law, and [*] will
indemnify and hold [*] harmless from any liability incurred by [*] arising out
of any such actions or proceedings. [*] shall have the right to participate and
be represented in any such suit by its own counsel [*]. No settlement of any
such action or defense which restricts the scope, or adversely affects the
enforceability, of a BMS Patent Right may be entered into by [*] without the
prior written consent of [*], which consent shall not be unreasonably withheld.
10.3.2 Enforcement [*]. If [*] elects not to bring any action for
infringement described in Section 10.3.1 and so notifies [*], then [*] may bring
such action at its own expense, in its own name and entirely under its own
direction and control. [*] will reasonably assist [*] in any action or
proceeding being prosecuted if so requested, and will lend its name to such
actions or proceedings if requested by [*] or required by law, and [*] will
indemnify and hold [*] harmless from any liability incurred by [*] arising out
of any such actions or proceedings. [*] shall have the right to participate and
be represented in any such suit by its own counsel [*]. No settlement of any
such action or defense which restricts the scope, or adversely affects the
enforceability, of a BMS Patent Right may be entered into by [*] without the
prior written consent of [*], which consent shall not be unreasonably withheld.
10.3.3 Withdrawal. If either Party brings such an action or defends
such a proceeding under this Section 10.3 and subsequently ceases to pursue or
withdraws from such action or proceeding, it shall promptly notify the other
Party and the other Party may substitute itself for the withdrawing Party under
the terms of this Section 10.3.
10.3.4 Damages. In the event either Party exercises the rights
conferred in this Section 10.3 and recovers any damages or other sums in such
action, suit or proceeding or in settlement thereof, such damages
or other sums recovered shall [*].
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-27-
10.4 DEFENSE OF THIRD PARTY CLAIMS. If a claim is brought by a Third Party
against either Party that any activity related to the Development, manufacture,
Commercialization, use, sale, import or export of a Compound or Product
infringes the intellectual property rights of such Third Party, each Party will
give prompt written notice to the other Party of such claim. The Royalty Paying
Party shall control [*], and shall be solely responsible for, and shall defend,
indemnify and hold harmless the Royalty Receiving Party and its Affiliates from
and against, any such claims, damages, losses, liabilities, costs (including
without limitation reasonable legal expenses, costs of litigation, and
reasonable attorney's fees) or judgments, whether for money or equitable relief.
ARTICLE 11
NONDISCLOSURE OF CONFIDENTIAL INFORMATION.
11.1 NONDISCLOSURE. Each Party agrees that for a period of [*] after
receipt of Confidential Information from the other Party, a Party receiving
Confidential Information of the other Party will (a) use commercially reasonable
efforts to maintain in confidence such Confidential Information (but not less
than those efforts as such Party uses to maintain in confidence its own
proprietary industrial information of similar kind and value) and not to
disclose such Confidential Information to any Third Party without prior written
consent of the other Party, except for disclosures made in confidence to any
Third Party under terms consistent with this Agreement and made in furtherance
of this Agreement or of rights granted to a Party hereunder, and (b) not use
such other Party's Confidential Information for any purpose except those
permitted by this Agreement (it being understood that this subsection (b) shall
not create or imply any rights or licenses not expressly granted under Article 2
hereof).
11.1.1 EXCEPTIONS. The obligations in Section 11.1 shall not apply
with respect to any portion of the Confidential Information that the receiving
Party can show by competent proof:
(a) Is publicly disclosed by the disclosing Party, either before
or after it is disclosed to the receiving Party hereunder; or
(b) Was known to the receiving Party or any of its Affiliates,
without obligation to keep it confidential, prior to disclosure by the
disclosing Party; or
(c) Is subsequently disclosed to the receiving Party or any of
its Affiliates by a Third Party lawfully in possession thereof and without
obligation to keep it confidential; or
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-28-
(d) Is published by a Third Party or otherwise becomes publicly
available or enters the public domain, either before or after it is disclosed to
the receiving Party; or
(e) Has been independently developed by employees or contractors
of the receiving Party or any of its Affiliates without the aid, application or
use of Confidential Information.
11.2 AUTHORIZED DISCLOSURE. A Party may disclose the Confidential
Information belonging to the other Party to the extent such disclosure is
reasonably necessary in the following instances:
11.2.1 Filing or prosecuting patents;
11.2.2 Regulatory filings;
11.2.3 Prosecuting or defending litigation;
11.2.4 Complying with applicable governmental laws and regulations and
with judicial process;
11.2.5 Disclosure, in connection with the performance of this
Agreement, to Affiliates, potential collaborators, partners, and counterparties
(including potential co-marketing and co-promotion contractors), research
collaborators, potential investment bankers, investors, lenders, and investors,
employees, consultants, or agents, each of whom prior to disclosure must be
bound by similar obligations of confidentiality and non-use at least equivalent
in scope to those set forth in this Section 11.2; and
11.2.6 For purposes of raising capital, provided that prior to
disclosure, each Third Party to whom Confidential Information is disclosed must
be bound by similar obligations of confidentiality and non-use at least
equivalent in scope to those set forth in this Section 11.2.
11.3 TERMS OF THIS AGREEMENT. The Parties acknowledge that the terms of
this Agreement shall be treated as Confidential Information of both Parties.
Such terms may be disclosed by a Party to individuals or entities covered by
Sections 11.2.5 and 11.2.6 above, each of whom prior to disclosure must be bound
by similar obligations of confidentiality and non-use at least equivalent in
scope to those set forth in this Section 11.3. In addition, a copy of this
Agreement may be filed by either Party with the Securities and Exchange
Commission in connection with any public offering of such Party's securities. In
connection with any such filing, such Party shall endeavor to obtain
confidential treatment of economic and trade secret information. In any event,
the Parties agree to take all reasonable action to avoid disclosure of
Confidential Information except as permitted hereunder.
11.4 EXCEPTION FOR DISCLOSURE [*]. Notwithstanding anything else in this
Agreement to the contrary, each Party hereto (and each employee, representative,
or other agent of any Party) may disclose to any and all persons, without
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-29-
limitation of any kind, [*] and all materials of any kind [*] that are or have
been provided to any Party (or to any employee, representative, or other agent
of any Party) relating to [*], provided, however, that this authorization of
disclosure shall not apply to restrictions reasonably necessary to comply with
securities laws. This authorization of disclosure is [*] and the Parties [*]
authorization has been given on [*].
ARTICLE 12
INDEMNITY
12.1 VANDA INDEMNITY. Vanda shall indemnify, defend and hold harmless BMS
and its Affiliates and the officers, directors, employees, agents, licensors
(including without limitation MGH and its officers, medical and professional
staff, employees, trustees, and agents and their respective successors, heirs
and assigns) and representatives of BMS and its Affiliates from and against
any and all claims, threatened claims, damages, losses, suits, proceedings,
liabilities, costs (including without limitation reasonable legal expenses,
costs of litigation, and reasonable attorney's fees) or judgments, whether for
money or equitable relief, of any kind ("Losses and Claims") arising out of or
relating to, directly or indirectly, [*] except for Losses and Claims to the
extent reasonably attributable to (i) breach by BMS of Article 11, or (ii) BMS
having committed an act or acts of gross negligence, recklessness, or willful
misconduct. A claim to which indemnification applies under this Section 12.1 or
Section 12.2 shall be referred to herein as an "Indemnification Claim".
12.2 BMS INDEMNITY. Only in the event that BMS exercises the BMS Option
with respect to a Product shall BMS indemnify, defend and hold harmless Vanda
and its Affiliates and the officers, directors, employees, agents, licensors and
representatives of Vanda and its Affiliates from Losses and Claims arising out
of or relating to, directly or
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-30-
indirectly, [*] except for Losses and Claims to the extent reasonably
attributable to (i) breach by Vanda of Article 11, or (ii) Vanda having
committed an act or acts of gross negligence, recklessness, or willful
misconduct.
12.3 INDEMNIFICATION PROCEDURES. If a party or any its Affiliates or their
respective officers, directors, employees, agents, licensors and representatives
(collectively, the "Indemnitee") intends to claim indemnification under this
Article 12, the Indemnitee shall notify the other party (the "Indemnitor") in
writing promptly upon becoming aware of any Claim that may be an Indemnification
Claim. The Indemnitor shall have the right to assume and control the defense of
the Indemnification Claim at its own expense. If the right to assume and have
sole control of the defense is exercised by the Indemnitor, the Indemnitee shall
have the right to participate in, but not control, such defense at its own
expense and the Indemnitor's indemnity obligations shall not include any
attorneys' fees and litigation expenses incurred by the Indemnitee after the
assumption of the defense by the Indemnitor. If the Indemnitor does not assume
the defense of the Indemnification Claim, the Indemnitee may defend the
Indemnification Claim but shall have no obligation to do so. The Indemnitee will
not settle or compromise the Indemnification Claim without the prior written
consent of the Indemnitor, and the Indemnitor will not settle or compromise the
Indemnification Claim in any manner which would have an adverse effect on the
Indemnitee's rights under this Agreement or the scope or enforceability of the
BMS Patents Rights or BMS Know-How, without the prior written consent of the
Indemnitee, which consent, in each case, will not be unreasonably withheld. The
Indemnitee shall reasonably cooperate with the Indemnitor at the Indemnitor's
expense and will make available to the Indemnitor all pertinent information
under the control of the Indemnitee.
12.4 INSURANCE. Vanda will, beginning with the initiation of the first
clinical trial for the Product, maintain at all times thereafter during the term
of this Agreement, and until the later of (a) [*] after termination or
expiration of this Agreement or (b) the date that all statutes of limitation
covering claims or suits that may be brought for personal injury based on the
sale or use of a Product have expired in all states in the U.S.A., [*] insurance
from a [*], and with coverage limits of not less than [*] per occurence and [*]
in the aggregate. The minimum level of insurance set forth herein shall not be
construed to create a limit on Vanda's liability hereunder. Within [*] following
written request
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-31-
from BMS, Vanda shall furnish to BMS a certificate of insurance evidencing such
coverage as of the date. Each such certificate of insurance, as well as any
certificates evidencing new or modified coverages of Vanda, shall include a
provision whereby [*] written notice must be received by BMS prior to coverage
modification or cancellation by either Vanda or the insurer and of any new or
modified coverage. In the case of a modification or cancellation of such
coverage, Vanda shall promptly provide BMS with a new certificate of insurance
evidencing that Vanda's coverage meets the requirements in the first sentence of
this Section.
ARTICLE 13
TERM AND TERMINATION
13.1 TERM. This Agreement shall commence upon the Effective Date and,
unless sooner terminated in accordance with the terms hereof or by mutual
written consent, shall continue until neither Party has any obligation to the
other remaining hereunder.
13.2 TERMINATION BY BMS. BMS shall have the right to terminate this
Agreement, at BMS' sole discretion, upon delivery of written notice to Vanda,
upon the occurrence of any of the following:
13.2.1 INSOLVENCY. Upon the filing by Vanda in any court or agency
pursuant to any statute or regulation of the United States or any other
jurisdiction a petition in bankruptcy or insolvency or for reorganization or
similar arrangement for the benefit of creditors or for the appointment of a
receiver or trustee of Vanda or its assets, upon the proposal by Vanda of a
written agreement of composition or extension of its debts, or if Vanda is
served with an involuntary petition against it in any insolvency proceeding,
upon the [*] after such service if such involuntary petition has not previously
been stayed or dismissed, or upon the making by Vanda of an assignment for the
benefit of its creditors; or
13.2.2 BREACH. In the event of any material breach by Vanda of any
terms and conditions of this Agreement, including failure to use Commercially
Reasonable Efforts to Develop or Commercialize a Product or Compound, provided
that such breach has not been cured within [*] after written notice thereof is
given by BMS to Vanda; provided, that if such breach relates to the failure to
make a payment when due, such breach must be cured within [*] after written
notice thereof is given by BMS.
13.2.3 TERMINATION FOR FAILURE TO EFFECT COMMERCIAL LAUNCH. If Vanda
is obligated to Commercialize a Product and fails to effect a commercial launch
in a Major Market Country within [*] of achieving an Approval for such Product
in such country; provided however, (i) that if the failure to launch in such
Major Market Country is a consequence of [*] and provided, further, (ii) that
subpart (i) of this Section
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-32-
13.2.3 may not be used to excuse launch, with respect to the [*]. Termination
under this Section 13.2.3 shall apply only to the [*] affected by such failure
to launch; provided, that (iii) if such failure relates to a [*] and (iv) [*]
Nothing in the foregoing shall relieve Vanda of its obligation to use
Commercially Reasonable Efforts to Commercialize a Product once launched in a
country.
13.2.4 SCOPE OF TERMINATION. Termination under Sections 13.2.1 and
13.2.2 shall be as to all countries and all Products.
13.3 TERMINATION BY VANDA. Subject to Section 13.3.4, Vanda shall have the
right to terminate this Agreement, at Vanda's sole discretion, upon delivery of
written notice to BMS, upon occurrence of any of the following:
13.3.1 TERMINATION FOR ANY REASON. At Vanda's discretion, on a
country-by-country and Product-by-Product basis, it may terminate this Agreement
for any reason; provided however, such termination shall be effective not sooner
than [*] after written notice thereof; and further provided, however, that no
such termination right may be exercised as-to-any Major Market Country unless
all Major Market Countries are so terminated unless such termination in a Major
Market Country is a consequence of lack of commercial feasibility in such Major
Market Country due to the pricing/reimbursement received for the Product in such
Country, in which event Vanda may terminate its license in such Major Market
Country only.
13.3.2 TERMINATION FOR BMS' FAILURE TO EFFECT COMMERCIAL LAUNCH. If
BMS is obligated to Commercialize a Product and fails to effect a commercial
launch within [*] of achieving the first Approval for such Product in a given
Major Market Country; provided however, if the failure to launch in such Major
Market Country is a consequence of lack of commercial feasibility due to the
pricing/reimbursement received for the Product in such Country or safety issues,
then this Section 13.3 shall not apply to such failure to launch.
13.3.3 TERMINATION FOR BMS' CESSATION OF DEVELOPMENT. If BMS elects to
cease development of a Product in its discretion with respect to a given Major
Market Country for a period exceeding [*] (other than for safety reasons or
regulatory reasons).
13.3.4 SCOPE OF TERMINATION. Termination under Sections 13.3.2 and
13.3.3 shall only be as to the countries affected by the BMS action in question
and not to the entire agreement (unless such BMS action affects all Major Market
Countries).
13.4 EFFECT OF TERMINATION.
13.4.1 Upon termination of this Agreement under Section 13.2.1 or
13.2.2 hereof or, with respect to each applicable country as to which
termination occurs pursuant to Section 13.2.3 or 13.3.1 hereof (the rights of
Vanda in the remaining countries of the
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-33-
Territory in which termination under Section 13.2.3 or 13.3.1 has not occurred
being unaffected by such termination):
(a) All rights and licenses granted to Vanda in Article 2 shall
terminate with respect to each terminated country, all rights, title and
interests to the BMS Patent Rights and BMS Know-How in each terminated country
shall revert to BMS, and Vanda shall cease all use of the BMS Patent Rights and
BMS Know-How with respect to each terminated country; and
(b) All regulatory filings (including all INDs and NDAs) and
Approvals relating to the Compounds and any Product (and all of Vanda's rights,
title and interests therein) in each terminated country shall be assigned to
BMS, and Vanda shall provide to BMS one copy of all documents and filings
contained in or referenced in any such filings, together with the raw and
summarized data for any preclinical and clinical studies of the Compounds and
Products. BMS shall have the right to obtain specific performance of Vanda's
obligations referenced in this Section 13.4.1(b) and/or in the event of failure
to obtain assignment, Vanda hereby consents and grants to BMS the right to
access and reference (without any further action required on the part of Vanda,
whose authorization to file this consent with any Regulatory Authority is hereby
granted) any and all such regulatory filings for any regulatory or other use or
purpose in each terminated country; and
(c) All amounts due or payable to BMS that were accrued, or that
arise out of acts or events occurring, prior to the effective date of
termination shall remain due and payable; but no additional amounts will be
payable based on events occurring after the effective date of termination; and
(d) BMS shall have the right to retain all amounts previously
paid to BMS by Vanda; and
(e) Should Vanda have any inventory of Compound suitable for use
in clinical trials in each terminated country, Vanda shall offer to sell such
Compound to BMS [*] (but BMS shall be under no obligation to purchase same
unless it agrees to do so in writing at such time); and
(f) Should Vanda have any inventory of Product approved and
allocated prior to termination for sale in a terminated country, Vanda shall
have [*] thereafter in which to dispose of such inventory (subject to the
payment to BMS of any royalties due hereunder thereon);
(g) Vanda will disclose to BMS its manufacturing patents,
processes, techniques and trade secrets for making the Product and BMS will
automatically have an exclusive, perpetual, worldwide, sublicensable right and
license under know-how and patents Controlled by Vanda and its Affiliates
relating to any composition, formulation, method of use or manufacture of the
Compounds and Products solely for (i) using, importing, selling and offering for
sale the Compounds and Products in the terminated countries and (ii) making and
having made the Compounds and
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-34-
Products anywhere in the world for use, importation, sale and offer for sale in
the terminated countries;
(h) Vanda shall assign to BMS any trademark or trade dress that
is specific to a Product (it being understood that the foregoing shall not
include any trademarks or tradenames that contain the name "Vanda") in each
terminated country;
(i) Vanda shall assign to BMS its right, title and interest in
any Sole Inventions and Joint Inventions (and any patent applications filed
thereon and patents issued thereon) pertaining to the composition of matter or
method of use or utility of the Compounds or Products in each terminated
country; and
(j) Neither Party shall be relieved of any obligation that
accrued prior to the effective date of such termination.
It is understood and agreed that BMS shall be entitled to specific performance
as a remedy to enforce the provisions of this Section 13.4.1, in addition to any
other remedy to which it may be entitled by applicable law.
13.4.2 In the event Vanda terminates the Agreement, in whole or in
part (in accordance with Section 13.3.4), pursuant to Section 13.3.2 or 13.3.3:
(a) BMS shall xxxxx Xxxxx all necessary rights and licenses on
the same terms and conditions set forth in Article 2, to the BMS Patent Rights
and BMS Know-How solely for use in a terminated country; and
(b) All regulatory filings (including all INDs and NDAs) and
Approvals relating to the Compounds and any Product (and all of BMS' rights,
title and interests therein) in a terminated country shall be assigned to Vanda,
and BMS shall provide to Vanda one copy of all documents and filings contained
in or referenced in any such filings, together with the raw and summarized data
for any preclinical and clinical studies of the Compounds and Products. In the
event of failure to obtain assignment, BMS hereby consents and grants to Vanda
the right to access and reference (without any further action required on the
part of BMS, whose authorization to file this consent with any Regulatory
Authority is hereby granted) any and all such regulatory filings for any
regulatory or other use or purpose with respect to each terminated country; and
(c) All amounts due or payable to Vanda that were accrued, or
that arise out of acts or events occurring, prior to the effective date of
termination shall remain due and payable, but no additional amounts will be
payable based on events occurring after the effective date of termination; and
(d) Vanda shall have the right to retain all amounts
previously paid to Vanda by BMS; and
(e) BMS shall assign to Vanda any trademark or trade dress that
is specific to a Product in such terminated country (it being understood that
the
-35-
foregoing shall not include any trademarks or tradenames that contain the name
"BMS"); and
(f) Vanda shall thereafter pay milestones and royalties to BMS
in accordance with Sections 8.2.1 and 8.5.1.
The remedies set forth in this Section 13.4.2 shall be Vanda's sole and
exclusive remedy for breach by BMS of its Development and/or Commercialization
obligations under this Agreement.
13.5 SURVIVAL. Except as expressly provided herein, the following
provisions shall survive early termination of this Agreement, as well as any
other provisions which by their nature are intended to survive termination:
Sections 4.2, 8.9.2, 9.4, 9.5, 10.1, 10.2, 10.4, 12.1, 12.2, 12.3, 12.4,
13.4.1(b), 13.4.1(f), 13.4.1(g), 13.4.2(b), 13.4.2(f), 13.5 and 13.6 and
Articles 11 and 14.
13.6 BANKRUPTCY.
13.6.1 All rights and licenses granted under or pursuant to this
Agreement, including amendments hereto, by each Party to the other Party are,
for all purposes of Section 365(n) of Title 11 of the U.S. Code ("TITLE 11"),
licenses of rights to intellectual property as defined in Title 11. Each Party
agrees during the term of this Agreement to create and maintain current copies
or, if not amenable to copying, detailed descriptions or other appropriate
embodiments, to the extent feasible, of all such intellectual property. If a
case is commenced by or against either Party (the "BANKRUPT PARTY") under Title
11, then, unless and until this Agreement is rejected as provided in Title 11,
the Bankrupt Party (in any capacity, including debtor-in-possession) and its
successors and assigns (including, without limitation, a Title 11 Trustee)
shall, at the election of the Bankrupt Party made within 60 days after the
commencement of the case (or, if no such election is made, immediately upon the
request of the non-Bankrupt Party) either (i) perform all of the obligations
provided in this Agreement to be performed by the Bankrupt Party including,
where applicable and without limitation, providing to the non-Bankrupt Party
portions of such intellectual property (including embodiments thereof) held by
the Bankrupt Party and such successors and assigns or otherwise available to
them or (ii) provide access or a license to the non-Bankrupt Party to all such
intellectual property (including all embodiments thereof) held by the Bankrupt
Party and such successors and assigns or otherwise available to them.
13.6.2 If a Title 11 case is commenced by or against the Bankrupt
Party and this Agreement is rejected as provided in Title 11 and the
non-Bankrupt Party elects to retain its rights hereunder as provided in Title
11, then the Bankrupt Party (in any capacity, including debtor-in-possession)
and its successors and assigns (including, without limitation, a Title 11
Trustee) shall provide access or a license to the non-Bankrupt Party to all such
intellectual property (including all embodiments thereof) held by the Bankrupt
Party and such successors and assigns or otherwise available to them immediately
upon the non-Bankrupt Party's written request therefor. Whenever the Bankrupt
Party or any of its successors or assigns provides access or a license to the
non-
-36-
Bankrupt Party to any of the intellectual property licensed hereunder (or any
embodiment thereof) pursuant to this Section 13.7, the non-Bankrupt Party shall
have the right to perform the obligations of the Bankrupt Party hereunder with
respect to such intellectual property, but neither such provision nor such
performance by the non-Bankrupt Party shall release the Bankrupt Party from any
such obligation or liability for failing to perform it.
13.6.3 All rights, powers and remedies of the non-Bankrupt Party
provided herein are in addition to and not in substitution for any and all other
rights, powers and remedies now or hereafter existing at law or in equity
(including, without limitation, Title 11) in the event of the commencement of a
Title 11 case by or against the Bankrupt Party. The non-Bankrupt Party, in
addition to the rights, power and remedies expressly provided herein, shall be
entitled to exercise all other such rights and powers and resort to all other
such remedies as may now or hereafter exist at law or in equity (including,
without limitation, under Title 11) in such event. The Parties agree that they
intend the foregoing non-Bankrupt Party rights to extend to the maximum extent
permitted by law and any provisions of applicable contracts with Third Parties,
including without limitation for purposes of Title 11, (i) the right of access
or a license to any intellectual property (including all embodiments thereof) of
the Bankrupt Party or any Third Party with whom the Bankrupt Party contracts to
perform an obligation of the Bankrupt Party under this Agreement, and, in the
case of the Third Party, which is necessary for the development, registration
and manufacture of licensed products and (ii) the right to contract directly
with any Third Party described in (i) in this sentence to complete the
contracted work. Any intellectual property provided pursuant to the provisions
of this Section 13.6 shall be subject to the licenses set forth elsewhere in
this Agreement and the payment obligations of this Agreement, which shall be
deemed to be royalties for purposes of Title 11.
ARTICLE 14
MISCELLANEOUS
14.1 PROVISIONS CONTRARY TO LAW. In performing this Agreement, the Parties
shall comply with all applicable laws. Wherever there is any conflict between
any provision of this Agreement and any law, the law shall prevail, but in such
event the affected provision of this Agreement shall be limited or eliminated
only to the extent necessary, and the remainder of this Agreement shall remain
in full force and effect. In the event the terms of this Agreement are
materially altered as a result of the foregoing, the Parties shall renegotiate
in good faith the terms of this Agreement to resolve any inequities.
14.2 THIRD PARTY RIGHTS. Notwithstanding anything to the contrary in this
Agreement, the grant of rights by BMS under this Agreement shall be subject to
and limited in all respects by the terms of the applicable BMS in-license(s)
pursuant to which BMS acquired any licensed rights, and all rights or
sublicenses granted under this Agreement shall be limited to the extent that BMS
may grant such rights and sublicenses under such BMS in-license(s).
-37-
14.3 NOTICES. Any notice required or permitted to be given by this
Agreement shall be in writing and shall be delivered by hand or overnight
courier with tracking capabilities or mailed postage prepaid by first class,
registered or certified mail addressed as set forth below unless changed by
notice so given:
If to Vanda:
Vanda Pharmaceuticals, Inc.
00 Xxxxxxx Xxxxxx, Xxxxx 000
Xxxxxxxxx, Xxx Xxxxxx 00000
Attention: President
If to BMS:
Xxxxxxx-Xxxxx Squibb Company
Xxxxx 000 xxx Xxxxxxxx Xxxx Xxxx
Xxxxxxxxx, Xxx Xxxxxx 00000
Attention: Senior Vice President for Business Development
With a copy to the Vice President and Senior Counsel, Corporate and
Business Development, at the same address.
Any such notice shall be deemed delivered on the date received. A Party may
add, delete, or change the person or address to whom notices should be sent at
any time upon written notice delivered to the Party's notices in accordance with
this Section 14.3.
14.4 FORCE MAJEURE. Neither Party shall be liable for delay or failure in
the performance of any of its obligations hereunder if such delay or failure is
due to causes beyond its reasonable control, including, without limitation, acts
of God, fires, earthquakes, strikes and labor disputes, acts of war, civil
unrest or intervention of any governmental authority; provided, that the
affected Party promptly notifies the other Party and further provided that the
affected Party shall use its commercially reasonable efforts to avoid or remove
such causes of non-performance and shall continue performance with the utmost
dispatch whenever such causes are removed. When such circumstances arise, the
Parties shall negotiate in good faith any modifications of the terms of this
Agreement that may be necessary or appropriate in order to arrive at an
equitable solution.
14.5 USE OF NAMES. Vanda, at its sole cost and expense, shall be
responsible for the selection, registration and maintenance of all trademarks
which it employs in connection with its activities conducted pursuant to this
Agreement, if any, and shall own and control such trademarks. Nothing in this
Agreement shall be construed as a grant to Vanda of rights, by license or
otherwise, to the use of any trademarks, service marks, logos or the name of BMS
for any purpose. Neither Party shall use the name or marks or logos of the other
Party for any purpose without the prior written consent of such other Party.
-38-
14.6 ASSIGNMENT. Neither Party shall assign its rights or obligations under
this Agreement without the prior written consent of the Party, except that:
14.6.1 BMS may, without Vanda's consent, assign all of its rights and
obligations hereunder in connection with any transfer of all of the BMS Patent
Rights and BMS Compound Know-How, to any Affiliate of BMS or another Third
Party, (including, without limitation, a successor in interest); provided, that
such Affiliate or assignee or successor in interest agrees in a writing provided
to Vanda to be bound by the terms of this Agreement; and
14.6.2 Upon [*] advance written notice to BMS and subject to BMS
approval, not to be unreasonably withheld, conditioned, or delayed, Vanda may
assign all of its rights and obligations hereunder to an entity of equal or
superior financial condition as Vanda or to an Affiliate (and so long as such
assignment includes, without limitation, the Approvals, all manufacturing assets
relating to this Agreement, and all rights and obligations under this
Agreement), provided, that such entity or Affiliate shall have agreed prior to
such assignment to be bound by the terms of this Agreement in a writing provided
to BMS and provided that Vanda remains jointly and severally liable with such
entity or Affiliate for the performance of this Agreement where assigned to a
Third Party or an Affiliate;
14.6.3 Vanda may assign all of its rights and obligations hereunder
without such consent to a successor in interest by reason of merger,
consolidation or sale of substantially all of the assets of Vanda (and so long
as such assignment or sale includes, without limitation, the Approvals, all
manufacturing assets relating to this Agreement, and all rights and obligations
under this Agreement), provided, that such successor in interest shall have
agreed prior to such assignment or sale to be bound by the terms of this
Agreement in a writing provided to BMS; and
14.6.4 Subject to the foregoing, this Agreement shall inure to the
benefit of and be binding on the Parties' successors and assigns. Any assignment
in violation of the foregoing shall be null and void and wholly invalid, the
assignee in any such assignment shall acquire no rights whatsoever, and the
non-assigning Party shall not recognize, nor shall it be required to recognize,
such assignment
14.7 FURTHER ASSURANCES. Each Party agrees to do and perform all such
further acts and things and shall execute and deliver such other agreements,
certificates, instruments and documents necessary or that the other Party may
deem advisable in order to carry out the intent and accomplish the purposes of
this Agreement and to evidence, perfect or otherwise confirm its rights
hereunder.
14.8 WAIVERS AND MODIFICATIONS. The failure of any Party to insist on the
performance of any obligation hereunder shall not be deemed to be a waiver of
such obligation. Waiver of any breach of any provision hereof shall not be
deemed to be a waiver of any other breach of such provision or any other
provision on such occasion or any succeeding occasion. No waiver, modification,
release or amendment of any
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-39-
obligation under or provision of this Agreement shall be valid or effective
unless in writing and signed by all Parties hereto.
14.9 CHOICE OF LAW AND JURISDICTION.
14.9.1 This Agreement shall be governed by, enforced, and shall be
construed in accordance with the laws of the State of New York without regard
to its conflicts of law provisions (other than section 5.1401 of the New York
General Obligations Law).
14.9.2 Each Party irrevocably submits to the exclusive jurisdiction of
(a) the Supreme Court of the State of New York, New York County, and (b) the
United States District Court for the Southern District of New York, for the
purposes of any suit, action or other proceeding arising out of this Agreement
or out of any transaction contemplated hereby. Each Party agrees to commence any
such action, suit or proceeding either in the United States District Court for
the Southern District of New York or if such suit, action or other proceeding
may not be brought in such court for jurisdictional reasons, in the Supreme
Court of the State of New York, New York County. Each Party further agrees that
service of any process, summons, notice or document by personal delivery, by
registered mail, or by a recognized international express delivery service to
such Party's respective address set forth above shall be effective service of
process for any action, suit or proceeding in New York with respect to any
matters to which it has submitted to jurisdiction in this Section 14.9. Each
Party irrevocably and unconditionally waives any objection to the laying of
venue of any action, suit or proceeding arising out of this Agreement or the
transactions contemplated hereby in (i) the Supreme Court of the State of New
York, New York County or (ii) the United States District Court for the Southern
District of New York, and hereby and thereby further irrevocably and
unconditionally waives and agrees not to plead or claim in any such court that
any such action, suit or proceeding brought in any such court has been brought
in an inconvenient forum.
14.9.3 Each Party hereto hereby waives to the fullest extent permitted
by applicable law, any right it may have to a trial by jury in respect to any
litigation directly or indirectly arising out of, under or in connection with
this Agreement. Each Party hereto (a) certifies that no representative, agent or
attorney of the other Party has represented, expressly or otherwise, that such
other Party would not, in the event of litigation, seek to enforce that
foregoing waiver and (b) acknowledges that it and the other Party hereto have
been induced to enter into this Agreement, as applicable, by, among other
things, the mutual waivers and certifications in this Section 14.9.
14.10 PUBLICITY.
14.10.1 Subject to Article 11, except as required by law, regulation
or order, including, without limitation, laws, regulations and orders of the
U.S. Securities and Exchange Commission, the National Association of Securities
Dealers or any national stock exchange, and except as expressly provided herein,
neither Vanda nor BMS shall make any public announcement concerning this
Agreement, including but not
-40-
limited to the execution of this Agreement and the economic terms of this
Agreement, without the prior written consent of the other Party. In the event of
a public disclosure required by law or regulation, including without limitation,
any required disclosure in any securities offering document, the Party making
such announcement shall at least five business days prior to such disclosure
provide the other Party with a copy of the proposed text of the disclosure, and
such other Party shall be entitled to have its reasonable comments incorporated
prior to such announcement, provided that provision of proposed text and
incorporation of comments referenced above is consistent with the disclosing
Party's legal or regulatory obligations.
14.10.2 Notwithstanding the foregoing, in the event that Vanda decides
that it would like to issue a public announcement regarding the execution of
this Agreement following such execution, Vanda shall submit the proposed form of
such public announcement to BMS for its review and written approval. Absent such
approval of BMS, Vanda may not make such a public announcement.
14.11 ENTIRE AGREEMENT. This Agreement constitutes the entire agreement
between the Parties as to the subject matter of this Agreement, and supersedes
and merges all prior negotiations, representations, agreements and
understandings regarding the same.
14.12 COUNTERPARTS. This Agreement may be executed in counter-parts with
the same effect as if both Parties had signed the same document. All such
counterparts shall be deemed an original, shall be construed together and shall
constitute one and the same instrument.
14.13 RELATIONSHIP OF THE PARTIES. Each Party is an independent contractor
under this Agreement. Nothing contained herein is intended or is to be construed
so as to constitute BMS and Vanda as partners, agents or joint venturers.
Neither Party shall have any express or implied right or authority to assume or
create any obligations on behalf of or in the name of the other Party or to bind
the other Party to any contract, agreement or undertaking with any Third Party.
14.14 HEADINGS. Headings and captions are for convenience only and are not
be used in the interpretation of this Agreement. Neither this Agreement nor any
provision of this Agreement shall be construed for or against any Party because
the Agreement as a whole, or any portion of it, was requested or drafted by such
Party.
14.15 DISPUTE RESOLUTION. In the event of any dispute relating to this
Agreement, prior to instituting any lawsuit, arbitration or other dispute
resolution process on account of such dispute, the Parties shall attempt in good
faith to settle such dispute first by negotiation and consultation between
themselves, including referral of such dispute to the Chief Executive Officer of
Vanda and the (a) President of the Pharmaceutical Research Institute of BMS for
any dispute involving Development, or (b) the President of U.S. Primary Care of
BMS for any dispute involving Commercialization. In the event said executives
are unable to resolve such dispute or agree upon a mechanism to resolve such
dispute within thirty (30) days of the first written request for dispute
resolution under this
-41-
Section 14.15, then the Parties shall be free to pursue any remedy or rights
available to either of them at law or in equity.
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by
their respective duly authorized officers.
VANDA PHARMACEUTICALS, INC.
By:
------------------------------------
(Signature)
Name: Xxxxxx Xxxxxxxxxxxxxx
Title: Chief Executive Officer
Date:
----------------------------------
XXXXXXX-XXXXX SQUIBB COMPANY
By:
------------------------------------
(Signature)
Name: Xxxxx Xxxxxx
Title: President, Pharmaceutical
Research Institute
Date:
----------------------------------
-42-
SCHEDULE 1.3
BMS COMPOUND PATENT RIGHTS AND DESCRIPTION OF THE COMPOUNDS
BMS-214778 is a [*].
BMS-330446 is a [*].
BMS Compound Patent Rights for BMS-214778
[*]
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-43-
BMS Compound Patent Rights for BMS-330446
[*]
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-44-
SCHEDULE 1.7
BMS MANUFACTURING PATENT RIGHTS
None
-45-
\
SCHEDULE 1.19
DEVELOPMENT PLAN
DEVELOPMENT TIMELINES FOR A PRODUCT CONTAINING BMS-214778
[*]
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-46-
BUDGET FOR A PRODUCT CONTAINING BMS-214778
[*]
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-47-
SCHEDULE 1.25
FTE RATE
[*]
----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO OTHER
PORTIONS
-48-
